MA37610B1 - Formulations de testostérone proliposomales - Google Patents
Formulations de testostérone proliposomalesInfo
- Publication number
- MA37610B1 MA37610B1 MA37610A MA37610A MA37610B1 MA 37610 B1 MA37610 B1 MA 37610B1 MA 37610 A MA37610 A MA 37610A MA 37610 A MA37610 A MA 37610A MA 37610 B1 MA37610 B1 MA 37610B1
- Authority
- MA
- Morocco
- Prior art keywords
- testosterone
- proliposomal
- testosterone formulations
- formulations
- proliposomal powder
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 6
- 229960003604 testosterone Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000006185 dispersion Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 238000009165 androgen replacement therapy Methods 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
La présente invention concerne de nouvelles formulations de testostérone dans lesquelles la testostérone est incorporée dans un système de phospholipide/cholestérol pour produire une dispersion de poudre proliposomale. Les dispersions de poudre proliposomales de l'invention peuvent être formulées avec des excipients pharmaceutiquement acceptables pour former des compositions pharmaceutiques. Les formes pharmaceutiques orales à enrobage entérique sont décrites ainsi que des procédés de traitement pour thérapie de remplacement de testostérone.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644996P | 2012-05-09 | 2012-05-09 | |
| PCT/US2013/040325 WO2013170012A2 (fr) | 2012-05-09 | 2013-05-09 | Formulations de testostérone proliposomales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37610A1 MA37610A1 (fr) | 2016-07-29 |
| MA37610B1 true MA37610B1 (fr) | 2017-07-31 |
Family
ID=49551459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37610A MA37610B1 (fr) | 2012-05-09 | 2013-05-09 | Formulations de testostérone proliposomales |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US8957053B2 (fr) |
| EP (1) | EP2846781B1 (fr) |
| JP (3) | JP6055088B2 (fr) |
| KR (1) | KR20150032939A (fr) |
| CN (2) | CN108096192A (fr) |
| AP (1) | AP2014008099A0 (fr) |
| AR (1) | AR091006A1 (fr) |
| AU (2) | AU2013259509B2 (fr) |
| BR (1) | BR112014027942A2 (fr) |
| CA (1) | CA2872779A1 (fr) |
| CL (1) | CL2014003034A1 (fr) |
| CO (1) | CO7240373A2 (fr) |
| CR (1) | CR20140561A (fr) |
| DO (1) | DOP2015000026A (fr) |
| EA (2) | EA201791738A1 (fr) |
| EC (1) | ECSP14030572A (fr) |
| GE (1) | GEP201706754B (fr) |
| HK (2) | HK1210409A1 (fr) |
| IL (1) | IL235464B (fr) |
| IN (1) | IN2014DN10383A (fr) |
| MA (1) | MA37610B1 (fr) |
| MX (1) | MX367123B (fr) |
| MY (1) | MY175305A (fr) |
| NZ (2) | NZ702634A (fr) |
| PE (1) | PE20150203A1 (fr) |
| PH (1) | PH12014502498A1 (fr) |
| SG (2) | SG11201407349UA (fr) |
| TN (1) | TN2014000467A1 (fr) |
| TW (2) | TWI614035B (fr) |
| UA (1) | UA115058C2 (fr) |
| WO (1) | WO2013170012A2 (fr) |
| ZA (2) | ZA201408996B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10213440B2 (en) | 2014-08-20 | 2019-02-26 | Professional Compounding Centers Of America (Pcca) | Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor |
| KR101682821B1 (ko) | 2015-07-21 | 2016-12-06 | 서울대학교산학협력단 | 프로리포솜 제조방법 |
| EA038653B1 (ru) * | 2016-01-07 | 2021-09-29 | Вестерн Юниверсити Оф Хелт Сайенсиз | Составы для лечения рака мочевого пузыря |
| CN108601736A (zh) * | 2016-01-08 | 2018-09-28 | 健康科学西部大学 | 前体脂质体十一酸睾酮制剂 |
| KR102574139B1 (ko) | 2016-07-07 | 2023-09-05 | 삼성전자주식회사 | 무선 충전 모드를 변경하는 장치 및 방법 |
| CR20190274A (es) | 2016-11-11 | 2019-07-29 | Univ Western Health Sciences | Formulaciones liposomales para interacciones farmacológicas contra carcinoma del tracto superior |
| IL274579B2 (en) | 2017-11-17 | 2025-04-01 | Evonik Operations Gmbh | Process for making a capsule with a coated hard shell |
| US10716774B1 (en) | 2018-01-05 | 2020-07-21 | Yale Pharmaceuticals LLC | Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability |
| CA3107214A1 (fr) | 2018-07-20 | 2020-01-23 | Lipocine Inc. | Maladie du foie |
| WO2020069450A1 (fr) * | 2018-09-28 | 2020-04-02 | Joel Studin | Administration à travers les pores de médicaments et utilisations associées |
| EP3968969B1 (fr) * | 2019-05-15 | 2025-10-01 | Evonik Operations GmbH | Procédé de remplissage de capsules à enveloppe dure à revêtements de copolymères de (méth)acrylate avec une machine de remplissage de capsules |
| CN113993508A (zh) * | 2019-05-15 | 2022-01-28 | 赢创运营有限公司 | 用胶囊填充机制备具有基于纤维素或淀粉的包衣的填充硬壳胶囊的方法 |
| AU2020329775A1 (en) * | 2019-08-09 | 2022-02-24 | Tesorx Pharma, Llc | Proliposomal testosterone undecanoate formulations |
| CN110747271B (zh) * | 2019-12-02 | 2023-07-18 | 延边大学 | 关于pci术后血管损伤-再狭窄程度的标记物 |
| JP6945874B2 (ja) * | 2019-12-24 | 2021-10-06 | 一般財団法人バイオダイナミックス研究所 | 経口投与用医薬組成物 |
| CN111840240A (zh) * | 2020-05-29 | 2020-10-30 | 仁和堂药业有限公司 | 一种非那雄胺制剂及其应用 |
| CN112121003B (zh) * | 2020-09-29 | 2022-02-01 | 江苏集萃新型药物制剂技术研究所有限公司 | 缓释制剂载药材料及其组合物、缓释制剂及其制备方法 |
| WO2022245650A1 (fr) * | 2021-05-19 | 2022-11-24 | Alberto Paz | Compositions administrées par voie orale pour le traitement du cancer |
| CN114668719B (zh) * | 2022-02-21 | 2023-06-16 | 广东食品药品职业学院 | 双氢睾酮混悬剂与双氢睾酮冻干粉及其制备方法 |
| TW202417004A (zh) * | 2022-09-16 | 2024-05-01 | 大陸商長春金賽藥業有限責任公司 | 類固醇激素磷脂組合物及其製備方法 |
| CN117018211B (zh) * | 2023-07-31 | 2025-09-09 | 沈阳药科大学 | 一种睾酮-胆固醇前药及制备方法和应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US5002936A (en) | 1985-04-12 | 1991-03-26 | Seymour Lieberman | Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds |
| US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| CA1337397C (fr) | 1988-09-29 | 1995-10-24 | Hideo Nakajima | Composition emulsifiee |
| IE904098A1 (en) | 1989-11-13 | 1991-05-22 | Nova Pharm Corp | Lipospheres for controlled delivery of substances |
| US20040175417A1 (en) | 1990-10-19 | 2004-09-09 | Gilead Sciences, Inc. | Amphotericin B liposome preparation |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| JP3017906B2 (ja) | 1993-10-08 | 2000-03-13 | 信越化学工業株式会社 | 腸溶性コーティング剤分散液 |
| US6214375B1 (en) | 1996-07-16 | 2001-04-10 | Generex Pharmaceuticals, Inc. | Phospholipid formulations |
| US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US6761901B1 (en) * | 2000-05-02 | 2004-07-13 | Enzrel Inc. | Liposome drug delivery |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| WO2002051426A2 (fr) | 2000-12-22 | 2002-07-04 | A Glenn Braswell | Compositions et methodes permettant de traiter des dysfonctions sexuelles, d'ameliorer l'activite sexuelle et d'augmenter les niveaux de testosterone, et d'ameliorer la force et la masse musculaires |
| US6534080B2 (en) | 2001-02-12 | 2003-03-18 | Super Gen, Inc. | Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin |
| US8658202B2 (en) * | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
| US20040115226A1 (en) | 2002-12-12 | 2004-06-17 | Wenji Li | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same |
| JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| EP1624857A2 (fr) | 2003-05-12 | 2006-02-15 | Novosom AG | Reserves injectables constituees d'agregats liposomaux pour l'administration de principes actifs |
| JP4787165B2 (ja) | 2003-11-05 | 2011-10-05 | エラン ファーマ インターナショナル，リミティド | 表面安定剤としてペプチドを有するナノ粒子組成物 |
| US20060051406A1 (en) | 2004-07-23 | 2006-03-09 | Manjeet Parmar | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| WO2006062506A1 (fr) * | 2004-12-03 | 2006-06-15 | Enzrel, Inc. | Administration de composes antioxydants ou anti-inflammatoires au moyen d'un medicament liposomal enrobe de chitosane |
| US8246984B2 (en) | 2005-12-06 | 2012-08-21 | Rigel Pharmaceuticals, Inc. | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| US20070154403A1 (en) | 2006-01-05 | 2007-07-05 | Thomas Skold | Oral, Pulmonary and Transmucosal Delivery Composition |
| NZ572308A (en) | 2006-03-30 | 2011-09-30 | Univ New York State Res Found | Compositions of less immunogenic and long-circulating protein-lipid complexes |
| AU2008227852B2 (en) * | 2007-03-19 | 2011-02-24 | Fresenius Kabi Oncology Ltd. | Proliposomal and liposomal compositions |
| US11304960B2 (en) * | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| WO2012058668A2 (fr) * | 2010-10-29 | 2012-05-03 | Western University Of Health Sciences | Formulations de mélange ternaire |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| WO2013026002A1 (fr) | 2011-08-18 | 2013-02-21 | Monosol Rx, Llc | Systèmes d'administration d'hormone stéroïde et procédés de préparation de ceux-ci |
-
2013
- 2013-05-09 MX MX2014013450A patent/MX367123B/es active IP Right Grant
- 2013-05-09 KR KR1020147034548A patent/KR20150032939A/ko not_active Ceased
- 2013-05-09 MY MYPI2014703308A patent/MY175305A/en unknown
- 2013-05-09 PE PE2014002002A patent/PE20150203A1/es active IP Right Grant
- 2013-05-09 CA CA2872779A patent/CA2872779A1/fr not_active Abandoned
- 2013-05-09 CN CN201810024730.3A patent/CN108096192A/zh active Pending
- 2013-05-09 EP EP13787438.4A patent/EP2846781B1/fr active Active
- 2013-05-09 TW TW102116691A patent/TWI614035B/zh not_active IP Right Cessation
- 2013-05-09 AU AU2013259509A patent/AU2013259509B2/en not_active Ceased
- 2013-05-09 AP AP2014008099A patent/AP2014008099A0/xx unknown
- 2013-05-09 AR ARP130101616A patent/AR091006A1/es unknown
- 2013-05-09 WO PCT/US2013/040325 patent/WO2013170012A2/fr not_active Ceased
- 2013-05-09 NZ NZ702634A patent/NZ702634A/en not_active IP Right Cessation
- 2013-05-09 GE GEAP201313659A patent/GEP201706754B/en unknown
- 2013-05-09 BR BR112014027942A patent/BR112014027942A2/pt active Search and Examination
- 2013-05-09 JP JP2015511696A patent/JP6055088B2/ja not_active Expired - Fee Related
- 2013-05-09 CN CN201380032890.8A patent/CN104780914B/zh not_active Expired - Fee Related
- 2013-05-09 EA EA201791738A patent/EA201791738A1/ru unknown
- 2013-05-09 TW TW106138648A patent/TWI664982B/zh not_active IP Right Cessation
- 2013-05-09 EA EA201492047A patent/EA028809B1/ru not_active IP Right Cessation
- 2013-05-09 NZ NZ721900A patent/NZ721900A/en not_active IP Right Cessation
- 2013-05-09 HK HK15109133.2A patent/HK1210409A1/xx unknown
- 2013-05-09 SG SG11201407349UA patent/SG11201407349UA/en unknown
- 2013-05-09 IN IN10383DEN2014 patent/IN2014DN10383A/en unknown
- 2013-05-09 MA MA37610A patent/MA37610B1/fr unknown
- 2013-05-09 SG SG10201702240TA patent/SG10201702240TA/en unknown
- 2013-09-05 UA UAA201413186A patent/UA115058C2/uk unknown
-
2014
- 2014-01-07 US US14/149,227 patent/US8957053B2/en not_active Expired - Fee Related
- 2014-11-02 IL IL235464A patent/IL235464B/en active IP Right Grant
- 2014-11-04 TN TN2014000467A patent/TN2014000467A1/fr unknown
- 2014-11-07 CL CL2014003034A patent/CL2014003034A1/es unknown
- 2014-11-07 PH PH12014502498A patent/PH12014502498A1/en unknown
- 2014-12-04 CR CR20140561A patent/CR20140561A/es unknown
- 2014-12-08 ZA ZA2014/08996A patent/ZA201408996B/en unknown
- 2014-12-09 EC ECIEPI201430572A patent/ECSP14030572A/es unknown
- 2014-12-09 CO CO14270756A patent/CO7240373A2/es unknown
-
2015
- 2015-01-26 US US14/604,985 patent/US9445995B2/en not_active Expired - Fee Related
- 2015-02-12 DO DO2015000026A patent/DOP2015000026A/es unknown
- 2015-12-22 ZA ZA2015/09340A patent/ZA201509340B/en unknown
-
2016
- 2016-08-29 US US15/250,169 patent/US9623033B2/en not_active Expired - Fee Related
- 2016-09-19 US US15/268,917 patent/US9844557B2/en not_active Expired - Fee Related
- 2016-12-01 JP JP2016234097A patent/JP6208842B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-07 JP JP2017172142A patent/JP6368020B2/ja not_active Expired - Fee Related
- 2017-11-29 US US15/825,530 patent/US20180303850A1/en not_active Abandoned
- 2017-12-07 AU AU2017272249A patent/AU2017272249B2/en not_active Ceased
-
2018
- 2018-11-23 HK HK18114995.6A patent/HK1255929A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37610B1 (fr) | Formulations de testostérone proliposomales | |
| MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
| MA33299B1 (fr) | Nouvelle formulation de naproxène | |
| NZ716421A (en) | Drug for treatment of nonalcoholic fatty liver disease | |
| TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
| MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
| MA35285B1 (fr) | Indazoles | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA44674A (fr) | Inhibiteurs de bromodomaine | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201170036A1 (ru) | Соединения боронатного эфира и его фармацевтические составы | |
| MA32686B1 (fr) | Composés, compositions et procédés pour le traitement de maladies de la b-amyloïde et de synucléinopathies | |
| MA35716B1 (fr) | Formulations pharmaceutiques | |
| MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| IN2014DN06869A (fr) | ||
| EA201490544A1 (ru) | Препараты и лекарственные формы на основе окисленных фосфолипидов | |
| EP2651450A4 (fr) | Formulations pharmaceutiques d'azole pour administration parentérale et procédés pour préparer et utiliser celles-ci en tant que traitement de maladies sensibles à des composés azole | |
| MA38646A1 (fr) | Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa. | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MA34867B1 (fr) | Nouvelle association entre le 4-{3-[c/s-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un antigoniste des recepteurs nmda et les compositions pharmaceutiques qui la contiennent | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |